The Biobank Economic Modeling Tool (BEMT): Online Financial Planning to Facilitate Biobank Sustainability

Biopreservation and Biobanking

Volumn 13, Issue 6, 2015, Pages 421-429

  Odeh, Hana ^a,b   Miranda, Lisa ^c   Rao, Abhi ^a   Vaught, Jim ^a,d   Greenman, Howard ^e   McLean, Jeffrey ^f   Reed, Daniel ^g   Memon, Sarfraz ^a   Fombonne, Benjamin ^a,b   Guan, Ping ^a   Moore, Helen M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Kelly Government Solutions   (United States)

^c Biobusiness Consulting Inc   (United States)

^d Gray Cary Ware and Freidenrich   (United States)

^e Provia Laboratories LLC   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g Wrycan Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASSESSMENT OF HUMANS; BIBLIOGRAPHIC DATABASE; BIOBANK; BIOBANK ECONOMIC MODELING TOOL; FUNDING; HEALTH SURVEY; HUMAN; INFORMATION SYSTEM; INVESTMENT; PLANNING; PRIORITY JOURNAL; SALARY; COST; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; FACTUAL DATABASE; FINANCIAL MANAGEMENT; INTERNET; NATIONAL HEALTH ORGANIZATION; ORGANIZATION; ORGANIZATION AND MANAGEMENT; QUESTIONNAIRE; SOFTWARE; TRANSLATIONAL RESEARCH; UNITED STATES;

ACADEMIES AND INSTITUTES; BIOLOGICAL SPECIMEN BANKS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; FINANCIAL MANAGEMENT; INTERNET; MODELS, ECONOMIC; NATIONAL CANCER INSTITUTE (U.S.); SOFTWARE; SURVEYS AND QUESTIONNAIRES; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84952785486     PISSN: 19475535     EISSN: 19475543     Source Type: Journal    
DOI: 10.1089/bio.2015.0089     Document Type: Article

References (19)

1. Hamburg MA, Collins FS. The path to personalized medicine. N Eng J Med 2010;363:301-304.
2. Aldridge S. Biobanking emerging as a key growth area. Present challenges and future benefits addressed. Genet Engineer Biotech News (GEN) 2005;25:1-2.
3. Vaught J. Economics: The neglected ''omics'' of niobanking. Biopreserv Biobank 2013;11:259.
4. Rogers J, Carolin T, Vaught J, Compton C. Biobankonomics: A taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research. J Natl Cancer Inst Monogr 2011;2011:32-38.
5. Vaught J, Rogers J, Carolin T, Compton C. Biobankonomics: Developing a sustainable business model approach for the formation of a human tissue biobank. J Natl Cancer Inst Monogr 2011;2011:24-31.
6. Clément B, Yuille M, Zaltoukal K, et al. Public biobanks: Calculation and recovery of costs. Sci Transl Med 2014; 6:261fs245.
7. Betsou F, Rimm DL, Watson PH, et al. What are the biggest challenges and opportunities for biorepositories in the next three to five years? Biopreserv Biobank 2010;8:81-88.
8. Puchois PM, Miranda LB, Van Gool A. The cardinal role of biobanks and human biospecimen collections in biomarker validation: Issues impeding impact of biomarker research outcomes. Royal Soc Chem 2013;73-110.
9. Park O, Cho S, Shin SY, Park JS, Kim JW, Han BG. A strategic plan for the second phase (2013-2015) of the Korea biobank project. Osong Public Health Res Persp 2013;4:107-116.
10. International Society for Biological and Environmental Repositories (ISBER). 2012 Best Practices for Repositories: Collection, Storage, Retrieval, And Distribution of Biological Materials for Research. Biopreserv Biobank 2012;10:79-161.
11. National Institutes of Health, National Cancer Institute (NCI), Biorepositories and Biospecimen Research Branch (BBRB). NCI Best Practices for Biospecimen Resources 2011; http://biospecimens. cancer. gov/practices/. Last accessed 15 October 2015.
12. Cadigan RJ, Lassiter D, Haldeman K, Conlon I, Reavely E, Henderson GE. Neglected ethical issues in biobank management: Results from a U. S. study. Life Sci Soc Policy 2013;9:1.
13. Watson PH, Nussbeck SY, Carter C, et al. A framework for biobank sustainability. Biopreserv Biobank 2014;12:60-68.
14. Matzke L, Dee S,Bartlett J, et al. Apractical tool formodeling biospecimen user fees. Biopreserv Biobank 2014;12:234-239.
15. McDonald SA, Sommerkamp K, Egan-Palmer M, Kharasch K, Holtschlag V. Fee-for-service as a business model of growing importance: The academic biobank experience. Biopreserv Biobank 2012;10:421-425.
16. Barnes RO, Schacter B, Kodeeswaran S, Committee CTM, Watson PH. Funding sources for Canadian biorepositories: The role of user fees and strategies to help fill the gap. Biopreserv Biobank 2014;12:300-305.
17. Kozlakidis Z, Mant C, Cason J. Bridging the financial gap through providing contract services: A model for publicly funded clinical biobanks. Biopreserv Biobank 2012;10: 357-360.
18. Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003-2008. JAMA2010;303:137-143.
19. Bromley RL. Financial stability in biobanking: Unique challenges for disease-focused foundations and patient advocacy organizations. Biopreserv Biobank. 2014;12:294-299.